Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases

Wei-Chin Chang,1,2,3,4 Yu Zhi Zhang,1,5 Janina L Wolf,6 Sergei M Hermelijn,7 J Marco Schnater,7 Jan H von der Thüsen,6 Alexandra Rice,1,5 Sylvie Lantuejoul,8,9 Bénédicte Mastroianni,10 Carol Farver,11 Fiona Black,12 Sanjay Popat5,13,14 & Andrew G Nicholson1,5,15

1Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust, London, UK, 2Department of Pathology, MacKay Memorial Hospital, Taipei, 3Department of Medicine, MacKay Medical College, New Taipei City, Taipei, 4Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, 5National Heart and Lung Institute, Imperial College, London, UK, 6Department of Pathology, Erasmus Medical Centre, Sophia Children’s Hospital, Rotterdam, 7Department of Paediatric Surgery, Erasmus Medical Centre, Sophia Children’s Hospital, Rotterdam, The Netherlands, 8Department of Biopathology, Cancer Centre of Léon Bérard, Lyon, 9Grenoble Alpes University, Grenoble, 10Department of Medicine, Cancer Centre of Léon Bérard, Lyon, France, 11Department of Pathology, University of Michigan, Ann Arbor, MI, USA, 12Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, 13Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, and 14Institute of Cancer Research, London, UK

Date of submission 6 June 2020
Accepted for publication 16 August 2020
Published online Article Accepted 18 August 2020

Chang W-C, Zhi Zhang Y, Wolf J L, Hermelijn S M, Schnater J M, von der Thüsen J H, Rice A, Lantuejoul S, Mastroianni B, Farver C, Black F, Popat S & Nicholson A G. (2021) Histopathology 78, 434–444. https://doi.org/10.1111/his.14239

Aims: Mucinous adenocarcinoma arising in congenital pulmonary airway malformation (CPAM) is a rare complication, with little being known about its natural course. The aims of this article are to describe a series of mucinous adenocarcinomas arising from CPAMs, and present their clinicopathological features, genetics, and clinical outcome.

Methods and results: Thirty-seven cases were collected within a 34-year period, and the subtype of adenocarcinoma and CPAM, tumour location, stage, growth patterns, molecular data and follow-up were recorded. The cohort comprised CPAM type 1 (n = 33) and CPAM type 2 (n = 4). Morphologically, 34 cases were mucinous adenocarcinomas (21 in situ; 13 invasive), and three were mixed mucinous and non-mucinous adenocarcinoma. Seventeen cases showed purely extracystic (intra-alveolar) adenocarcinoma, 15 were mixed intracystic and extracystic, and five showed purely intracystic proliferation. Genetically, nine of 10 cases tested positive for KRAS mutations, four with exon 2 G12V mutation and five with exon 2 G12D mutation. Residual disease on completion lobectomy was observed in two cases, and three cases recurred 7, 15 and 32 years after the original diagnosis. Two patients died of metastatic invasive mucinous adenocarcinoma.

Conclusions: Most adenocarcinoma that arise in type 1 CPAMs, are purely mucinous, and are early-stage disease. Intracystic proliferation is associated with lepidic growth, an absence of invasion, and indolent behaviour, whereas extracystic proliferation may be associated with more aggressive behaviour and...
advanced stage. Most cases are cured by lobectomy, and recurrence/residual disease seems to be associated with limited surgery. Long-term follow-up is needed, as recurrence can occur decades later. Keywords: adenocarcinoma, congenital pulmonary airway malformation, KRAS, mucinous, prognosis

Introduction

Congenital pulmonary airway malformation (CPAM) is a rare cystic lesion composed of architecturally disordered respiratory structures, with the latest reported incidence being 1/2500. Stocker originally described three histological subtypes: the number of subtypes was later expanded to five, although type 0 CPAM is more commonly accepted as acinar dysplasia, and type 4 CPAMs are now viewed as regressed pleuropulmonary blastomas by some. Type 2 CPAMs are the most common, and are composed of bronchiole-like cysts <20 mm in cyst size surrounded by underdeveloped/simplified alveolar parenchyma. They are often associated with pulmonary sequestrations. Type 1 CPAMs are rarer, and are composed of one or more cysts >20 mm in diameter, accompanied by smaller cysts and alveolar parenchyma similar to that in type 2 CPAMs.

A proliferation of cytologically bland mucinous cells within the cyst lining is observed in approximately one-third of cases, mostly in type 1 CPAMs, but also rarely in type 2 and 3 CPAMs. These lesions have historically been classified as goblet or mucous cell hyperplasia, mucinous epithelial proliferation, mucinous metaplasia, and atypical goblet cell hyperplasia (AGCH). Occasionally, the mucinous cells also grow along the alveolar septa into the adjacent, sometimes underdeveloped, alveoli; this is microscopically indistinguishable from mucinous adenocarcinoma in situ (AIS) or invasive mucinous adenocarcinoma (IMA). With KRAS mutations having been reported in mucinous cells both within the cyst and in the adjacent alveoli, and rare reports of associated metastases and mixed mucinous and non-mucinous adenocarcinoma, these lesions are now accepted by some pathologists as neoplastic (either as AIS or IMA).

Although the nature of these lesions is better established, there are few data on the outcome and follow-up of these rare lesions, even in literature reviews. In this study, we describe a series of 37 mucinous adenocarcinoma cases arising from CPAMs, looking at the histopathological features (including growth patterns, nuclear features, and location of mucinous proliferation), genetic abnormalities, surgical procedures, and clinical follow-up data, with the aim of identifying key features and proposing recommendations that can be used for future management.

Materials and methods

Case selection

A review of the archives of the Royal Brompton Hospital (London, UK) and Erasmus University Medical Centre (Rotterdam, The Netherlands) for adenocarcinomas resected with associated cystic changes revealed 42 cases (Royal Brompton Hospital, n = 34; Erasmus University Medical Centre, n = 8) within a 34-year period, either as consultation cases (n = 18) or routine diagnostic cases (n = 24). Five cases were excluded as a result of insufficient evidence supporting the presence of a cystic lesion pre-dating tumour development, and were viewed as adenocarcinomas showing cystic change as part of their presentation. The slides for the remaining 37 cases were reviewed by three thoracic pathologists (W.-C.C., A.G.N., and J.H.T.), and the type of adenocarcinoma and CPAM, tumour location, location of mucinous proliferation (intracystic—defined as limited to bronchiole-like cystic areas lined by mainly respiratory-type cells; or extracystic—defined as extending into alveolar-like parenchyma lined by pneumocytes), growth patterns, nuclear atypia, necrosis, lymphovascular invasion, tumour spread through airspace (STAS), pleural invasion and synchronous atypical adenomatous hyperplasia (AAH) were recorded. Cases with more than one specimen all had tissue from both samples available for review. Clinical data, tumour staging and follow-up were also recorded. Five of these cases (cases 12, 15, 22, 26, and 28) have been previously reported in case reports or case series.

Mutational analyses

Detection of KRAS, EGFR and other mutations was performed on 11 cases as part of a routine clinical workup in five institutions (Royal Brompton Hospital, Erasmus University Medical Centre, and others). Mutational analysis of these cases revealed a high frequency of KRAS mutations (n = 10). Other mutations were rare, with only one case showing a mutation in EML4. None of the cases showed mutations in ALK, ROS1, or MET. In conclusion, this study provides valuable insight into the pathology and clinical outcomes of mucinous adenocarcinoma arising in CPAM.
Erasmus University Medical Centre, Oxford University Hospitals, Cancer Centre of Léon Bérard, and Centre Hospitalier Universitaire de Grenoble).

Statistical Analyses
Comparisons between continuous variables were performed with one-way ANOVA, and Fisher’s exact test and the chi-square test were used to assess associations between categorical variables. Statistical significance was considered to be present if the $P$-value was <0.05 (two-sided). All statistical analyses were performed with the SPSS statistical software package (v.25.0; SPSS, Chicago, IL, USA) and GRAPHPAD PRISM (v.8.3.0; GraphPad, La Jolla, CA, USA).

Results
Clinical Features
The patient cohort comprised 22 males and 15 females, and the mean age was 20.3 years (range, 0 days to 68 years), with 22 patients aged <18 years. The main presenting symptoms/signs were recurrent infections (n = 4), tachypnoea/dyspnoea (n = 4), cough (n = 3), pneumothorax (n = 2), chest discomfort (n = 3), and respiratory failure (n = 2). Two infant patients were intubated immediately after birth with a suspected diagnosis of congenital diaphragmatic hernia, diagnosed by the use of prenatal ultrasonography. The location of the cyst/tumour was available for 32 cases, with the predominant site being the left lower lobe (n = 10), followed by the right lower lobe (n = 8), the left lung, not stated (n = 5), the left upper lobe (n = 4), the right middle lobe (n = 3), the right upper and middle lobe (n = 1), and the right lung, not stated (n = 1). Tumour size ranged from 0.3 mm to 120 mm. Most patients underwent anatomical resections [lobectomy (n = 28), bilobectomy (n = 1), and pneumonectomy (n = 2)], with four cases treated with non-anatomical cyst resection. One patient underwent segmentectomy followed by lobectomy when adenocarcinoma was identified in the segmentectomy. One patient underwent biopsy of a mass in the lung contralateral to the cyst.

At the time of diagnosis, tumour stages at first presentation were stage 0 (pTis; n = 22), stage I (pT1 and pT2a; n = 9), stage II (pT2b and pT3; n = 3), and stage III (pT4; n = 2). One patient (case 28) was diagnosed with stage IV (cM1a) IMA on surgical lung biopsy of mass lesions arising in a background of preceding cystic lung disease. The clinical features are summarised in Table 1.

Histopathological Findings
With regard to the background cysts (Table 2), 33 were type 1 CPAMs and four were type 2 CPAMs, with smaller cysts being lined by bronchial/bronchiolo- lar epithelium separated by underdeveloped/simplified alveoli. In one case, mucinous adenocarcinoma was diagnosed on biopsy without sampling of the cyst, but there was unequivocal evidence of a cyst pre-dating development of the tumour. With regard to the tumours, 34 cases were purely mucinous adenocarcinomas, and three cases were mixed mucinous and non-mucinous adenocarcinomas. The majority were purely lepidic with mild nuclear atypia and no mitosis (Figure 1A,B). Of those with invasive patterns (n = 5; Figure 1C,D), all were lepidic-predominant with minor acinar, papillary or micropapillary patterns, showing mild to moderate nuclear atypia and increased mitotic activity. Two cases showed aerogenous spread into the adjacent alveoli, resembling STAS. Synchronous AAH was observed in the adjacent lung parenchyma in three cases. Necrosis, lymphovascular invasion and pleural invasion were not observed in any case. Of the four cases in which recurrence/residual tumour was observed, one (case 22) had both tumour and residual cyst in the completion lobectomy. The other three cases showed recurrent/residual tumour only (cases 7, 17, and 18). Surgical margins were not specifically sampled in the original CPAM specimen, so whether lesional tissue was present in the surgical margin could not be evaluated.

Tumour location was subdivided into involvement of cystic areas (intracystic) and extension into surrounding alveolar parenchyma (extracystic). Five cases were purely intracystic, 15 cases showed predominantly extracystic growth with a minor intracystic component (Figure 1B), and 17 cases were purely extracystic (Figure 1C,D; Table 2). Mixed mucinous and non-mucinous cell types, STAS and synchronous AAH were more likely to be seen in cases with purely or predominantly extracystic growth, although the difference did not reach statistical significance (Table 3).

Molecular Findings
Molecular testing was performed in 11 cases. Nine of 10 cases tested for KRAS mutations were positive, and showed either KRAS exon 2 G12V mutations (c.35G>T; cases 7, 9, 16, and 30) or KRAS exon 2 G12D mutations (c.35G>A; cases 28, 10, 12, 13, 18, and 28). In case 18, an additional GNAS p.R201H mutation was detected alongside the KRAS exon 2
| No. | Age   | Sex | Symptoms/signs                                      | Location | Treatment       | Size (mm) | TNM stage | Follow-up                      |
|-----|-------|-----|---------------------------------------------------|----------|-----------------|-----------|------------|--------------------------------|
| 1   | 0 days| M   | Respiratory failure                               | LUL      | Lobectomy       | 1.9       | pTisNx     | AFoD (63 months)               |
| 2   | 1 day | M   | NA                                                | Left     | Lobectomy       | 0.4       | pTisNx     | Postoperative death (1 day)    |
| 3   | 2 days| M   | Suspicion of congenital diaphragmatic hernia on prenatal ultrasonography | LUL      | Lobectomy       | 0.8       | pTisNx     | NA                             |
| 4   | 2 days| M   | Respiratory failure                               | Left     | Pneumonectomy   | 0.6       | pTisNx     | Postoperative death (12 days)  |
| 5   | 4 days| M   | Tachypnoea                                         | RLL      | Lobectomy       | 1.2       | pTisNx     | AFoD (99 months)               |
| 6   | 10 days| F   | Suspicion of congenital diaphragmatic hernia on prenatal ultrasound | Left     | Pneumonectomy   | 0.3       | pTisNx     | AFoD (61 months)               |
| 7   | 12 days| F   | Cyst resected in neonate                          | RUL/RML  | Bilobectomy of CPAM; wedge biopsy of M1a recurrence | 20        | pT1bNx     | M1a recurrence at 392 months, DoD (437 months) |
| 8   | 14 days| M   | Cyst resected in neonate                          | LUL      | Lobectomy       | 9         | pT1aNx     | NA                             |
| 9   | 21 days| M   | NA                                                | LLL      | Lobectomy       | 0.6       | pTisNx     | AFoD (13 months)               |
| 10  | 1 month| F   | Tachypnoea, dyspnoea, cough                        | RML      | Lobectomy       | 3         | pTisNx     | NA                             |
| 11  | 49 days| M   | Tachypnoea, dyspnoea, respiratory acidosis        | LLL      | Lobectomy       | 0.9       | pTisNx     | AFoD (30 months)               |
| 12  | 6 months| M   | No symptoms                                       | RLL      | Lobectomy       | 1         | pTisNx     | AFoD (385 months)              |
| 13  | 2 years| M   | NA                                                | NA       | Lobectomy       | 10        | pT1aNx     | AFoD (5 months)                |
| 14  | 2 years| F   | NA                                                | RLL      | Lobectomy       | 1         | pTisNx     | AFoD (25 months)               |
| 15  | 3 years| F   | Recurrent infections                              | LLL      | Lobectomy       | 2         | pTisNx     | NA                             |
| 16  | 4 years| F   | NA                                                | NA       | Lobectomy       | 1         | pTisNx     | AFoD (12 months)               |
| 17  | 11 years| F   | NA                                                | NA       | Segmentectomy, then completion lobectomy | 13        | pT1bNx     | Residual tumour in lobectomy, no further follow-up |
| 18  | 13 years| M   | Severe chronic asthma                             | LUL      | Non-anatomical cyst resection of CPAM; lobectomy for RLL recurrence | 45        | pT2bN0     | Recurrence at 15 years (with further lobectomy), AFoD (8 months after recurrence)* |
| 19  | 15 years| F   | NA                                                | RLL      | Lobectomy       | 20        | pT1bNx     | NA                             |
| 20  | 15 years| M   | Recurrent pneumothoraces                           | LLL      | Lobectomy       | 2         | pTisNx     | AFoD (2 months)                |
| 21  | 17 years| M   | NA                                                | NA       | Non-anatomical cyst resection | 2         | pTisNx     | NA                             |
G12D mutation observed in the original CPAM (Table 2). Four cases were tested for EGFR mutations and two for ALK rearrangement; all were negative.

**Clinical Follow-up**

Clinical follow-up data were available for 21 cases. Residual disease on completion lobectomy was observed in two patients (cases 17 and 22), one at 7 years and one in whom lobectomy followed segmentectomy. Two patients suffered recurrence at 32 years and 15 years after the initial diagnosis (cases 7 and 18); one of these (case 7) died 45 months after M1a recurrence. One patient (case 22) was found to have residual/recurrent disease 7 years (with further resection), AFoD (272 months) after initial non-anatomical resection. One patient (case 28) died 68 months after presenting with M1a disease. Two patients (cases 2 and 4) died postoperatively, and one patient (case 37) died 130 months after diagnosis, from an unknown cause.

**Discussion**

This study shows that adenocarcinomas arising in CPAMs are typically indolent mucinous AISs or IMAs.
Table 2. Histopathological and molecular features of mucinous adenocarcinomas arising in congenital pulmonary airway malformation (CPAM)

| No. | CPAM type | Cell type | Location* | Lepidic (%) | Acinar (%) | Papillary (%) | Micropapillary (%) | Atypia | Mitoses (/2 mm²) | STAS | AAH | KRAS |
|-----|-----------|-----------|-----------|-------------|------------|--------------|--------------------|-------|----------------|------|-----|-------|
| 1   | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 3              | No   | No  | NA    |
| 2   | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 3   | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 4   | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 5   | 2         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 6   | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 7   | 1         | Mucinous  | Intracystic/extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | G12V |
| 8   | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 4              | No   | No  | NA    |
| 9   | 2         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | G12V |
| 10  | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | G12D |
| 11  | 1         | Mucinous  | Intracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 12  | 1         | Mucinous  | Intracystic/extracystic | 100         | 0          | 0            | 0                  | Moderate | 1            | No   | No  | G12D |
| 13  | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Moderate | 1            | No   | No  | G12D |
| 14  | 1         | Mucinous  | Intracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 15  | 1         | Mucinous  | Intracystic/extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | WT    |
| 16  | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Moderate | 0            | No   | No  | G12V |
| 17  | 1         | Mixed     | Extracystic | 90          | 5          | 5            | 0                  | Moderate | 0            | No   | Yes | NA    |
| 18  | 2         | Mucinous  | Extracystic | 50          | 30         | 20           | 0                  | Moderate | 1            | No   | No  | G12D |
| 19  | 1         | Mixed     | Intracystic/extracystic | 100         | 0          | 0            | 0                  | Moderate | 0            | No   | No  | NA    |
| 20  | 1         | Mucinous  | Intracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 21  | 1         | Mucinous  | Intracystic/extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 22  | 1         | Mucinous  | Intracystic/extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 23  | 1         | Mucinous  | Intracystic/extracystic | 95          | 5          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 24  | 1         | Mixed     | Intracystic/extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | Yes | NA    |
| 25  | 2         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Moderate | 0            | No   | No  | NA    |
| 26  | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 27  | 1         | Mucinous  | Intracystic/extracystic | 100         | 0          | 0            | 0                  | Mild   | 0              | No   | No  | NA    |
| 28  | 1         | Mucinous  | Extracystic | 100         | 0          | 0            | 0                  | Mild   | 2              | No   | No  | G12D |

© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 434–444.
that are cured by anatomical resection of the cyst and surrounding lung, usually by lobectomy. However, some tumours show more aggressive histological subtypes, and, more importantly, independent of histology, can recur decades after initial resection of the cyst at an advanced stage, especially when resection is at a level less than lobectomy.

With regard to histopathological features, CPAMs with pure intracystic proliferation of mucinous adenocarcinoma cells are associated with lepidic growth and the absence of an invasive component, and all showed an indolent behaviour, with an excellent prognosis; in contrast, CPAMs with mixed intracystic/extracystic or pure extracystic mucinous proliferations were occasionally associated with invasive architectural patterns, STAS, and tumour recurrence or intrapulmonary metastasis. This suggests that the presence of extracystic mucinous proliferations alone should be viewed as a more aggressive feature even in the absence of stromal, pleural or vascular invasion, and a thorough examination of the resected specimen by the use of extensive sampling may be warranted to rule out invasive components elsewhere.

Anatomical lung resection has been recommended as the optimal treatment for CPAMs, given the risk of malignant transformation.25 In our series, there were four cases (cases 7, 17, 18, and 22; 10.8%) that had either residual disease on lobectomy or recurred years after the initial surgery; all but one initially received non-anatomical cyst resection. The ability of these mucinous adenocarcinoma cells to spread directly into alveolar parenchyma adjacent to the cystic areas and not be completely removed by non-anatomical resections is further exemplified by a case described by Summers et al.,14 in which an 8-year-old female with well-differentiated multifocal mucinous adenocarcinoma arising in CPAM diagnosed in the left lower lobe wedge biopsy was subsequently found to have residual tumour in the completion lobectomy and contralateral metastasis in the right lower lobe. Indeed, within a non-anatomical resection, it may be impossible with the naked eye at surgery or on preoperative imaging to definitively identify the border.

Table 2. (Continued)

| No. | CPAM type | Cell type | Location* | Lepidic (%) | Acinar (%) | Papillary (%) | Micropapillary (%) | Atypia | Mitoses (/2 mm²) | STAS | AAH | KRAS |
|-----|-----------|-----------|-----------|-------------|------------|---------------|-------------------|-------|-----------------|------|-----|------|
| 29  | Mucinous  | Intracystic/extracystic | 100 | 0 | 0 | 0 | Mild | 0 | No | Yes | NA |
| 30  | Mucinous  | Intracystic | 100 | 0 | 0 | 0 | Mild | 0 | No | No | G12V |
| 31  | Mucinous  | Intracystic/extracystic | 75 | 5 | 0 | 20 | Moderate | 3 | Yes | No | NA |
| 32  | Mucinous  | Intracystic/extracystic | 100 | 0 | 0 | 0 | Mild | 0 | No | No | NA |
| 33  | Mucinous  | Intracystic/extracystic | 95 | 5 | 0 | 0 | Moderate | 1 | No | No | NA |
| 34  | Mucinous  | Intracystic/extracystic | 100 | 0 | 0 | 0 | Mild | 0 | No | No | NA |
| 35  | Mucinous  | Intracystic | 100 | 0 | 0 | 0 | Mild | 0 | No | No | NA |
| 36  | Mucinous  | Intracystic/extracystic | 100 | 0 | 0 | 0 | Mild | 0 | No | No | NA |
| 37  | Mucinous  | Extracystic | 100 | 0 | 0 | 0 | Moderate | 0 | Yes | No | NA |

AAH, atypical adenomatous hyperplasia; G12D, exon 2 Gly12Asp; G12V, exon 2 Gly12Val; NA, not available; STAS, tumour spread through airspace; WT, wild type.

*Intracystic: tumour cells are intracystic (defined as cysts otherwise lined by respiratory-type epithelium). Extracystic: tumour cells are extracystic (defined as extending into adjacent alveolar parenchyma lined by pneumocytes). Intracystic/extracystic: tumour cells are present in both areas (the predominant area is in bold).
†Associated with an exon 8 p.R201H GNAS mutation in the recurrence.
‡Residual/recurrent tumour and residual CPAM in completion lobectomy.
§Based on cyst size on imaging.
between lesional and normal alveolar tissue outside of visible cysts. However, because cases with non-anatomical resection in our study were mostly historical cases without adequate sampling of the surgical margins, we were unable to confirm whether the resection margins contained residual CPAM lesional tissue. Given most CPAMs are lobar, with rare exceptions,26,27 anatomical resection would therefore seem more likely to achieve complete resection of the CPAM and any tumour therein. This is supported by a recent study of 44 infantile CPAMs with mucinous cell clusters in which resection by lobectomy was not associated with poor outcomes.27 Although the numbers are small, these cases illustrate the importance of anatomical lung resection when a mucinous adenocarcinoma arising in a CPAM is identified, especially when disease extends beyond the cyst wall. Notably, we found that AAH was also present in 8.3% of cases, and there have also been previous reports of non-mucinous adenocarcinomas with or without AAH arising in CPAMs.28,29 These preneoplastic changes suggest that lung parenchyma in the vicinity of the cysts may have an increased propensity to undergo neoplastic change, and a field carcinisation effect might be responsible for their evolutionary origin.

There is an ongoing debate concerning the appropriate terminology for describing these mucinous cell proliferations, with many reports using the World Health Organization (WHO) terminology of ‘mucinous adenocarcinoma’ (including our study),9,10,14,16,30 and two recent studies using the terms ‘AGCH’ and ‘mucinous cell clusters (MCCs)’ to describe the mucinous cells.7,27 Although some have argued that these proliferations should not be classified with the use of a malignant or premalignant term, this view seems to be primarily based on a lack of malignant behaviour if complete resection is performed.27 However, these proliferations are morphologically indistinguishable from those in adults, and this study shows evidence of recurrence and metastasis if complete resection is not performed, albeit with a very slow growth rate. In addition, genetic analysis has demonstrated that these mucinous cells frequently harbour mutations of KRAS, most commonly exon 2 G12D (c.35G>A), G12V (c.35G>T) and G12C (c.34G>T) mutations,7,9,10,13–16,30–32 which are similar to the KRAS mutations commonly found in mucinous adenocarcinomas arising de novo, typically in smokers.33–37 In addition to KRAS mutations, Lantuejoul et al. demonstrated loss of heterozygosity at the tumour suppressor genes FHIT, Rb, and p16INK4, not only in the

Figure 1. A, A few cases show purely focal intracystic proliferation of mucinous adenocarcinoma cells adjacent to respiratory epithelium, usually in a lepidic fashion (case 13). B, Mucinous adenocarcinoma cells growing in a lepidic pattern adjacent to a large cystic space lined by ciliated respiratory epithelium, consistent with type 1 congenital pulmonary airway malformation (case 6). C, Extracystic acinar growth set in a fibrotic stroma can be observed in some cases (case 27). D, Extracystic papillary or micropapillary growth may be present alongside lepidic growth in some cases (case 11).
extracystic component, but also in the intracystic component. Consistent with the previous studies, exon 2 G12D and G12V mutations were also detected in nine of 10 cases in our cohort, two of which eventually recurred 15 and 32 years later. Furthermore, STAS can also be observed in mucinous adenocarcinomas arising in CPAMs similar to those arising de novo, although the frequency is low (2/37; 5.4%). We therefore believe that it is more appropriate to use the WHO criteria for adenocarcinoma and AIS for these lesions, although we recognise that this is an area that requires more data in the hope of achieving a consensus.

The limitations of the current study are that the data are incomplete, being retrospective, spanning >30 years, and often being from referred cases with limited follow-up information. Nevertheless, outcomes for which data are available do provide information that helps to suggest the management of future cases in terms of type of resection and duration of follow-up. We also have a relative lack of genetic studies, but data on those tested show recurring KRAS mutations, similar to those in adults with IMAs.

In summary, most cases of adenocarcinomas complicating CPAMs are purely lepidic IMAs or mucinous AISs, predominantly arising in type 1 CPAMs, although there are rare type 2 or 3 cases. CPAMs limited to intracystic bronchiolar-type proliferation are associated with the absence of an invasive component and an excellent prognosis, whereas those with extracystic proliferation into alveolar tissues may be associated with more aggressive behaviour and advanced stage, even in the absence of stromal, pleural or lymphovascular invasion. Tumours share the same spectrum of KRAS mutations as those in adults with de-novo IMA, and further studies investigating the genetic stability of the background lung are warranted. Most cases are cured with lobectomy, but non-anatomical resection is associated with recurrence/residual disease. Long-term follow-up, the nature of which would probably be empirical and depend on factors including patient age, stage, and completeness of resection (R status), may be needed, as recurrence can occur decades later.

### Table 3. Subgroup comparison of histopathological features based on the location of mucinous proliferation

| Features                          | Intracystic (N = 5) | Intracystic/ extracystic (N = 15) | Extracystic (N = 17) | P-value |
|----------------------------------|---------------------|----------------------------------|----------------------|---------|
| CPAM type (n)                    |                     |                                  |                      |         |
| 1                                | 5                   | 15                               | 13                   | 0.071   |
| 2                                | 0                   | 0                                | 4                    |         |
| Cell type (n)                    |                     |                                  |                      |         |
| Mucinous                         | 5                   | 13                               | 16                   | 0.576   |
| Mixed                            | 0                   | 2                                | 1                    |         |
| Invasive component (n)           |                     |                                  |                      |         |
| Absent                           | 5                   | 12                               | 12                   | 0.366   |
| Present                          | 0                   | 3                                | 5                    |         |
| Nuclear atypia (n)               |                     |                                  |                      |         |
| Mild                             | 5                   | 11                               | 11                   | 0.295   |
| Moderate                         | 0                   | 4                                | 6                    |         |
| Severe                           | 0                   | 0                                | 0                    |         |
| Mitoses per 2 mm² (n)            |                     |                                  |                      |         |
| Range                            | 0                   | 0–3                              | 0–4                  | 0.395   |
| Mean (SD)                        | 0 (0)               | 0.33 (0.82)                      | 0.65 (1.22)          |         |
| STAS (n)                         |                     |                                  |                      |         |
| Absent                           | 5                   | 14                               | 16                   | 0.844   |
| Present                          | 0                   | 1                                | 1                    |         |
| Synchronous AAH (n)              |                     |                                  |                      |         |
| Absent                           | 5                   | 13                               | 16                   | 0.576   |
| Present                          | 0                   | 2                                | 1                    |         |

AAH, atypical adenomatous hyperplasia; CPAM, congenital pulmonary airway malformation; SD, standard deviation; STAS, tumour spread through airspace.

### Conflicts of interest

A. G. Nicholson has received: consultancy fees from Merck, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, BMS, Roche, and Abbvie; lecture fees from AstraZeneca; and research grant from Pfizer. S. Popat has received consultancy fees from BMS, Roche, Takeda, AstraZeneca, Pfizer, MSD, EMD Serono, Guardian Health, Abbvie, Boehringer Ingelheim, OncLive, Medscape, Incyte, Paradox Pharmaceuticals, Blueprint, and Lilly. S. Lantuejoul has received consultancy fees from MSD, AstraZeneca, BMS, and Lilly. Wei-Chin Chang has received consultancy fees from
Boehringer Ingelheim. The remaining authors declare no conflicts of interest.

Author contributions

Wei-Chin Chang co-designed the research study, analysed the data, performed the research, and wrote the paper. A. G. Nicholson co-designed the research study and critically reviewed the paper. Yu Zhi Zhang assisted in collecting the clinical follow-up data. J. L. Wolf, S. M. Hermelijn, J. M. Schnater, J. H. von der Thüsen, S. Lantuejoul, B. Mastroianni, C. Farver, F. Black and S. Popat contributed the consultation cases, clinical follow-up data, and molecular data.

Acknowledgements

We thank Dr Mark McCole of Oxford University Hospitals NHS Foundation Trust for his valuable case contribution. Parts of this study were presented at the 108th United States and Canadian Academy of Pathology annual meeting on 20 March 2019.

References

1. Stocker LJ, Wellesley DG, Stanton MP, Parasuraman R, Howe DT. The increasing incidence of foetal echogenic congenital lung malformations: an observational study. Prenat. Diagn. 2015; 35: 148–153.
2. Stocker JT, Madewell JE, Drake RM. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Hum. Pathol. 1977; 8: 155–171.
3. Stocker JT. Congenital pulmonary airway malformation: a new name and an expanded classification of congenital cystic adenomatoid malformation of the lung. Histopathology 2002; 41: 424–431.
4. Messinger YH, Stewart DR, Priest JR et al. Pulmonary lymphoid blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastosma Registry. Cancer 2015; 121: 276–285.
5. Pogoriler J, Swarr D, Kreiger P, Adzick NS, Peranteau W. Congenital cystic lung lesions: redefining the natural distribution of subtypes and assessing the risk of malignancy. Am. J. Surg. Pathol. 2019; 43: 47–55.
6. Desai S, Dusmet M, Ladas G et al. Secondary vascular changes in pulmonary sequestrations. Histopathology 2010; 57: 121–127.
7. Fakler F, Ayukutlu U, Brcic L et al. Atypical goblet cell hyperplasia occurs in CPAM 1, 2, and 3, and is a probable precursor lesion for childhood adenocarcinoma. Virchows Arch. 2020; 476: 843–854.
8. MacSweeney F, Papagiannopoulos K, Goldstraw P, Sheppard MN, Corrin B, Nicholson AG. An assessment of the expanded classification of congenital cystic adenomatoid malformations and their relationship to malignant transformation. Am. J. Surg. Pathol. 2003; 27: 1139–1146.
9. Singh G, Coffey A, Neely R et al. Pulmonary Kirsten rat sarcoma virus mutation positive mucinous adenocarcinoma arising in a congenital pulmonary airway malformation, mixed type 1 and 2. Am. Thorac. Surg. 2016; 102: e335–e337.
10. Koh J, Jung E, Jang SJ et al. Case of mucinous adenocarcinoma of the lung associated with congenital pulmonary airway malformation in a neonate. Korean J. Pediatr. 2018; 61: 30–34.
11. Stacher E, Ullmann R, Hallwedell I et al. Atypical goblet cell hyperplasia in congenital cystic adenomatoid malformation as a possible preneoplasia for pulmonary adenocarcinoma in childhood: a genetic analysis. Hum. Pathol. 2004; 35: 565–570.
12. Ramos SG, Barbosa GH, Tavora FR et al. Bronchioloalveolar carcinoma arising in a congenital pulmonary airway malformation in a child: case report with an update of this association. J. Pediatr. Surg. 2007; 42: E1–E4.
13. Lantuejoul S, Nicholson AG, Sartori G et al. Mucinous cells in type 1 pulmonary congenital cystic adenomatoid malformation as mucinous bronchioalveolar carcinoma precursors. Am. J. Surg. Pathol. 2007; 31: 961–969.
14. Summers RJ, Shehata BM, Bleacher JC, Stockwell C, Rapin K. Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation. J. Pediatr. Surg. 2010; 45: 2256–2259.
15. Rossi G, Gasser B, Sartori G et al. MUC5AC, cytokeratin 20 and HER2 expression and K-RAS mutations within mucinogenic growth in congenital pulmonary airway malformations. Histopathology 2012; 60: 1133–1143.
16. Stephanov O, Robert Y, De Fraipont F, Piolat C, Sartelet H. Mucinous adenocarcinoma with lepidic pattern and with K-RAS mutation in a new born with antenatal diagnosis of congenital pulmonary airway malformation. Histopathology 2018; 72: 530–531.
17. Ioachimescu OC, Mehta AC. From cystic pulmonary airway malformation, to bronchioalveolar carcinoma and adenocarcinoma of the lung. Eur. Respir. J. 2005; 26: 1183–1187.
18. Lantuejoul S, Ferretti GR, Goldstraw P, Hansell DM, Brambilla E, Nicholson AG. Metastases from bronchioalveolar carcinoma associated with long-standing type 1 congenital cystic adenomatoid malformations. A report of two cases. Histopathology 2006; 48: 204–206.
19. Casagrande A, Pederiva F. Association between congenital lung malformations and lung tumors in children and adults: a systematic review. J. Thorac. Oncol. 2016; 11: 1837–1845.
20. Fintelmann FJ, Brinkmann JK, Jeck WR et al. Tumor and extrathoracic malignancies: an important and relatively common imaging appearance of (early) lung cancer. Eur. Respir. Rev. 2018; 27: 180079.
21. Brierley J, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 8th ed. Chichester: Wiley, 2017.
22. Sheffield EA, Addis BJ, Corrin B, McCabe MM. Epithelial hyperplasia and malignant change in congenital lung cysts. J. Clin. Pathol. 1987; 40: 612–614.
23. West D, Nicholson AG, Colquhoun I, Pollock J. Bronchioloalveolar carcinoma in congenital cystic adenomatoid malformation of lung. Ann. Thorac. Surg. 2007; 83: 687–689.
24. Baird R, Pulligandia PS, Laberge JM. Congenital lung malformations: informing best practice. Semin. Pediatr. Surg. 2014; 23: 270–277.
26. Ben-Ishay O, Nicksa GA, Wilson JM, Buchmiller TL. Management of giant congenital pulmonary airway malformations requiring pneumonectomy. *Ann. Thorac. Surg.* 2012; 94:1073–1078.

27. Nelson ND, Litzky LA, Peranteau WH, Pogoriler J. Mucinous cell clusters in infantile congenital pulmonary airway malformations mimic adult mucinous adenocarcinoma but are not associated with poor outcomes when appropriately resected. *Am. J. Surg. Pathol.* 2020; 44:1118–1129.

28. Mani H, Shilo K, Galvin JR, Stocker JT, Franks TJ. Spectrum of precursor and invasive neoplastic lesions in type 1 congenital pulmonary airway malformation: case report and review of the literature. *Histopathology* 2007; 51:561–565.

29. Tetsumoto S, Kijima T, Morii E et al. Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement in congenital pulmonary airway malformation. *Clin. Lung Cancer* 2013; 14:457–460.

30. Kim MY, Kang CH, Park SH. Multifocal synchronous mucinous adenocarcinomas arising in congenital pulmonary airway malformation: a case report with molecular study. *Histopathology* 2014; 65:926–932.

31. Ishida M, Igarashi T, Teramoto K et al. Mucinous bronchioloalveolar carcinoma with K-ras mutation arising in type 1 congenital cystic adenomatoid malformation: a case report with review of the literature. *Int. J. Clin. Exp. Pathol.* 2013; 6:2597–2602.

32. Winters IP, Chiu SH, Paulek NK et al. Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of K-ras variant oncogenicity. *Nat. Commun.* 2017; 8:2053.

33. Maeshima A, Sakamoto M, Hirohashi S. Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation. *Virchows Arch.* 2002; 440:598–603.

34. Ichinokawa H, Ishii G, Nagai K et al. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. *Hum. Pathol.* 2013; 44:2636–2642.

35. Geles A, Gruber-Moesenbacher U, Quehenberger F et al. Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival. *Virchows Arch.* 2015; 467:675–686.

36. Shim HS, Kenedson M, Zheng Z et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. *J. Thorac. Oncol.* 2015; 10:1156–1162.

37. Boland JM, Maleszewski JJ, Wampler JA et al. Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/non-mucinous adenocarcinoma—a clinicopathological and molecular genetic study with survival analysis. *Hum. Pathol.* 2018; 71:8–19.

38. Chang WC, Zhang YZ, Lim E, Nicholson AG. Prognostic impact of histopathologic features in pulmonary invasive mucinous adenocarcinomas. *Am. J. Clin. Pathol.* 2020; 154:88–102.

39. Travis W, Brambilla E, Burke A, Marx A, Nicholson A eds. *World Health Organization classification of tumours of the lung, pleura, thymus and heart.* Lyon: IARC Press, 2015.

© 2020 The Authors. *Histopathology* published by John Wiley & Sons Ltd, *Histopathology*, 78, 434–444.